Coloplast Inkomsten in het verleden

Verleden criteriumcontroles 3/6

Coloplast is de winst gegroeid met een gemiddeld jaarlijks percentage van 4.9%, terwijl de Medical Equipment industrie de winst jaarlijks groeide met 9.7%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 8.9% per jaar. Het rendement op eigen vermogen van Coloplast is 28.2%, en het heeft een nettomarge van 18.7%.

Belangrijke informatie

4.9%

Groei van de winst

4.0%

Groei van de winst per aandeel

Medical Equipment Groei van de industrie	-1.7%
Inkomstengroei	8.9%
Rendement op eigen vermogen	28.2%
Nettomarge	18.7%
Volgende winstupdate	04 Feb 2025

Recente prestatie-updates uit het verleden

Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

May 21

Recent updates

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Nov 13

Earnings Update: Coloplast A/S (CPH:COLO B) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Nov 08

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Oct 18

Coloplast A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 23

Are Investors Undervaluing Coloplast A/S (CPH:COLO B) By 38%?

Aug 22

Subdued Growth No Barrier To Coloplast A/S' (CPH:COLO B) Price

Jul 17

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Jun 29

Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

May 21

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00

May 10

Analyst Estimates: Here's What Brokers Think Of Coloplast A/S (CPH:COLO B) After Its Interim Report

May 09

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Dec 04

Coloplast (CPH:COLO B) Strong Profits May Be Masking Some Underlying Issues

Nov 16

A Look At The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Sep 30

Is Coloplast (CPH:COLO B) A Risky Investment?

Jun 28

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 18% Below Its Share Price

Jun 10

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Mar 22

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 25% Below Its Share Price

Mar 01

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Dec 14

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Nov 26

Here's Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Looks Fair for the time being

Nov 25

Coloplast's (CPH:COLO B) Shareholders Will Receive A Bigger Dividend Than Last Year

Nov 11

With EPS Growth And More, Coloplast (CPH:COLO B) Makes An Interesting Case

Oct 25

Estimating The Fair Value Of Coloplast A/S (CPH:COLO B)

Aug 26

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Jul 27

Here's Why We Think Coloplast (CPH:COLO B) Is Well Worth Watching

Jul 12

Is There An Opportunity With Coloplast A/S' (CPH:COLO B) 45% Undervaluation?

May 23

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of kr.5.00

May 08

Opbrengsten en kosten

Hoe Coloplast geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

CPSE:COLO B Opbrengsten, kosten en inkomsten (DKK Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	27,030	5,052	10,069	913
30 Jun 24	26,303	4,967	9,675	925
31 Mar 24	25,526	4,965	9,252	901
31 Dec 23	25,001	4,868	8,934	889
30 Sep 23	24,500	4,783	8,632	872
30 Jun 23	24,333	4,784	8,581	858
31 Mar 23	24,074	4,801	8,550	864
31 Dec 22	23,515	4,626	8,272	877
30 Sep 22	22,579	4,706	7,800	866
30 Jun 22	21,620	4,781	7,336	856
31 Mar 22	20,606	4,746	6,828	819
31 Dec 21	19,857	4,896	6,446	774
30 Sep 21	19,426	4,825	6,249	755
30 Jun 21	18,916	4,561	6,098	723
31 Mar 21	18,500	4,304	5,938	720
31 Dec 20	18,570	4,241	5,993	725
30 Sep 20	18,544	4,197	6,086	708
30 Jun 20	18,572	3,949	6,113	698
31 Mar 20	18,752	4,020	6,199	691
31 Dec 19	18,330	3,974	6,118	680
30 Sep 19	17,939	3,873	5,970	692
30 Jun 19	17,555	4,119	5,753	686
31 Mar 19	17,181	3,999	5,626	671
31 Dec 18	16,815	3,896	5,488	663
30 Sep 18	16,449	3,845	5,375	640
30 Jun 18	16,195	3,816	5,315	619
31 Mar 18	15,882	3,778	5,211	605
31 Dec 17	15,728	3,791	5,104	594
30 Sep 17	15,528	3,797	4,994	574
30 Jun 17	15,287	3,211	4,880	565
31 Mar 17	15,061	3,279	4,785	551
31 Dec 16	14,780	3,264	4,731	521
30 Sep 16	14,681	3,143	4,693	509
30 Jun 16	14,563	1,297	4,690	494
31 Mar 16	14,417	1,028	4,627	477
31 Dec 15	14,264	927	4,583	458
30 Sep 15	13,909	899	4,488	442
30 Jun 15	13,502	3,162	4,343	437
31 Mar 15	13,096	3,241	4,220	418
31 Dec 14	12,666	2,407	4,088	406
30 Sep 14	12,428	2,390	4,002	390
30 Jun 14	12,184	2,298	3,959	375
31 Mar 14	12,008	2,220	3,944	370
31 Dec 13	11,833	2,874	3,889	382

Kwaliteitswinsten: COLO B heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (18.7%) COLO B } zijn lager dan vorig jaar (19.5%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van COLO B is de afgelopen 5 jaar met 4.9% per jaar gegroeid.

Versnelling van de groei: De winstgroei van COLO B over het afgelopen jaar ( 5.6% ) overtreft het 5-jarig gemiddelde ( 4.9% per jaar).

Winst versus industrie: De winstgroei COLO B over het afgelopen jaar ( 5.6% ) overtrof de Medical Equipment -sector 13%.

Rendement op eigen vermogen

Hoge ROE: Hoewel het rendement op eigen vermogen ( 28.16% ) van COLO B hoog is, is deze metriek vertekend vanwege hun hoge schuldenniveau.

Coloplast Inkomsten in het verleden

Verleden criteriumcontroles 3/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Third quarter 2024 earnings: EPS misses analyst expectations

Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

Second quarter 2024 earnings: EPS misses analyst expectations

Recent updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Earnings Update: Coloplast A/S (CPH:COLO B) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Final dividend increased to kr.17.00

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

President & CEO exercised options and sold kr.5.0m worth of stock

Executive Vice President of Growth exercised options to buy kr.28m worth of stock.

Coloplast A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Are Investors Undervaluing Coloplast A/S (CPH:COLO B) By 38%?

Third quarter 2024 earnings: EPS misses analyst expectations

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Subdued Growth No Barrier To Coloplast A/S' (CPH:COLO B) Price

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00

First half dividend of kr.5.00 announced

Analyst Estimates: Here's What Brokers Think Of Coloplast A/S (CPH:COLO B) After Its Interim Report

Coloplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24

Second quarter 2024 earnings: EPS misses analyst expectations

A Look At The Fair Value Of Coloplast A/S (CPH:COLO B)

There's Reason For Concern Over Coloplast A/S' (CPH:COLO B) Price

Is Coloplast (CPH:COLO B) A Risky Investment?

President & CEO exercised options and sold kr.13m worth of stock

First quarter 2024 earnings: Revenues in line with analyst expectations

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Estimating The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Coloplast A/S' (CPH:COLO B) Price Is Out Of Tune With Earnings

Coloplast A/S Approves the Distribution of Year-End Dividend

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast (CPH:COLO B) Strong Profits May Be Masking Some Underlying Issues

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Now 20% undervalued after recent price drop

A Look At The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Deputy Chairman recently bought kr.40m worth of stock

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

New minor risk - Shareholder dilution

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Is Coloplast (CPH:COLO B) A Risky Investment?

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 18% Below Its Share Price

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 25% Below Its Share Price

First quarter 2023 earnings: EPS misses analyst expectations

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Upcoming dividend of kr.15.00 per share

Here's Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Looks Fair for the time being

Less than half of directors are independent

Coloplast Announces Executive Changes

Coloplast's (CPH:COLO B) Shareholders Will Receive A Bigger Dividend Than Last Year

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

With EPS Growth And More, Coloplast (CPH:COLO B) Makes An Interesting Case

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Estimating The Fair Value Of Coloplast A/S (CPH:COLO B)

Third quarter 2022 earnings: Revenues exceed analyst expectations